Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods

International Journal of Pharmaceutics - Tập 272 Số 1-2 - Trang 1-10 - 2004
Sundeep Sethia1, Emilio Squillante1
1College of Pharmacy and Allied Health Professions, St. John’s University, 8000 Utopia Parkway, Jamaica, NY 11439, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Beach, 1999, Control of the physical form of salmeterol xinafoate, Org. Process Res. Dev., 3, 370, 10.1021/op990160z

Behme, 1991, Heat of fusion measurement of a low melting polymorph of carbamazepine that undergoes multiple-phase changes during differential scanning calorimetry analysis, J. Pharm. Sci., 80, 986, 10.1002/jps.2600801016

Bertillson, 1978, Clinical pharmacokinetics of carbamazepine, Clin. Pharmacokinet., 3, 128, 10.2165/00003088-197803020-00003

Ford, 1986, The current status of solid dispersions, Pharm. Acta Helv., 61, 69

Gallagher, 1989, Gas antisolvent recrystallization: a new process to recrystallize compounds in supercritical fluids, Am Chem. Soc. Symp. Ser., 406, 334

Higuchi, 1965, Phase-solubility techniques, Adv. Anal. Chem. Instrum., 4, 117

Kaplan, 1972, Biopharmaceutical considerations in drug formation design and evaluation, Drug Metab. Rev., 1, 15, 10.3109/03602537208993907

Khoo, 2000, The formulation of halofantrine as either non-solubilising PEG 6000 or solubilising lipid based solid dispersions: physical stability and absolute bioavailability assessment, Int. J. Pharm., 205, 65, 10.1016/S0378-5173(00)00485-3

Krahn, 1987, Relations between several polymorphic forms and the dihydrate of carbamazepine, Pharm. Acta Helv., 67, 247

Leuner, 2000, Improving drug solubility for oral delivery using solid dispersions, Eur. J. Pharm. Biopharm., 50, 47, 10.1016/S0939-6411(00)00076-X

Löbenberg, 2000, Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards, Eur. J. Pharm. Biopharm., 50, 3, 10.1016/S0939-6411(00)00091-6

Lowes, 1987, Physicochemical properties and X-ray structural studies of the trigonal polymorph of carbamazepine, J. Pharm. Sci., 76, 744, 10.1002/jps.2600760914

Matsumoto, 1999, Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinylacetate) in relation to indomethacin crystallization, Pharm. Res., 16, 1722, 10.1023/A:1018906132279

Mayersohn, 1966, New method of solid-state dispersion for increasing dissolution rates, J. Pharm. Sci., 55, 1323, 10.1002/jps.2600551138

Moneghini, 2001, Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterization, and in vitro dissolution, Int. J. Pharm., 222, 129, 10.1016/S0378-5173(01)00711-6

Nair, 2001, Influence of various drugs on the glass transition temperature of poly(vinylpyrrolidone): a thermodynamic and spectroscopic investigation, Int. J. Pharm., 225, 83, 10.1016/S0378-5173(01)00767-0

Nogami, 1966, Studies on powdered preparations. XVII. Dissolution rate of sulfonamides by rotating disk method, Chem. Pharm. Bull., 14, 329, 10.1248/cpb.14.329

Rustichelli, 2000, Solid-state study of polymorphic drugs: carbamazepine, J. Pharm. Biomed. Anal., 23, 41, 10.1016/S0731-7085(00)00262-4

Serajuddin, 1999, Solid dispersions of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs, J. Pharm. Sci., 88, 1058, 10.1021/js980403l

Sethia, 2002, Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method, J. Pharm. Sci., 91, 1948, 10.1002/jps.10186

Sethia, 2003, Solid dispersions: revival with greater possibilities and applications in oral drug delivery, Crit. Rev. Ther. Drug Carrier Syst., 20, 215, 10.1615/CritRevTherDrugCarrierSyst.v20.i23.40

Silverstein, R.M., Bassler, G.C., Morril, T.C., 1991. Spectrometric Identification of Organic Compounds. Wiley, New York, pp. 91–131.

Taylor, 1997, Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions, Pharm. Res., 14, 1691, 10.1023/A:1012167410376

Van den Mooter, 1998, Physico-chemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K30, Int. J. Pharm., 164, 67, 10.1016/S0378-5173(97)00401-8

Van den Mooter, 2001, Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25, Eur. J. Pharm. Sci., 12, 261, 10.1016/S0928-0987(00)00173-1

York, 1999, Strategies for particle design using supercritical fluid technologies, Pharm. Sci. Tech. Today, 2, 430, 10.1016/S1461-5347(99)00209-6